Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Nutraceutical Supplements in the Thyroid Setting: Health Benefits beyond Basic Nutrition

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Perinatal Whole Blood Zinc Status and Cytokines, Adipokines, and Other Immune Response Proteins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Vibeke Andersen
  • Uffe Holmskov
  • Signe Bek Sørensen
  • Mohamad Jawhara
  • Karina W Andersen
  • Anette Bygum
  • Lone Hvid
  • Jakob Grauslund
  • Jimmi Wied
  • Henning Glerup
  • Ulrich Fredberg
  • Jan Alexander Villadsen
  • Søren Geill Kjær
  • Jan Fallingborg
  • Seyed A G R Moghadd
  • Torben Knudsen
  • Jacob Broder Brodersen
  • Jesper Frøjk
  • Jens Frederik Dahlerup
  • Ole Haagen Nielsen
  • Robin Christensen
  • Anders Bo Bojesen
  • Grith Lykke Sorensen
  • Steffen Thiel
  • Nils J. Færgeman
  • Ivan Brandslund
  • Allan Stensballe
  • Erik Berg Schmidt
  • Andre Franke
  • David Ellinghaus
  • Philip Rosenstiel
  • Jeroen Raes
  • Berit Heitmann
  • Mette Boyé
  • Charlotte Lindgaard Nielsen
  • Lars Werner
  • Jens Kjeldsen
  • Torkell Ellingsen
Vis graf over relationer

Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

Udgave nummer5
StatusUdgivet - 15 maj 2017

ID: 50633115